852313-93-0

Usage

Uses

Used in Pharmaceutical Industry:
5-amino-1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonitrile is used as an intermediate in the synthesis of various bioactive molecules and pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 5-amino-1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonitrile serves as a valuable building block for the creation of complex organic molecules. Its reactivity and functional groups make it a useful component in the synthesis of a wide range of compounds.
Used in Agrochemical Development:
5-amino-1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonitrile may have potential uses in the development of agrochemicals, such as pesticides and herbicides. Its unique properties could contribute to the design of novel and effective products for agricultural applications.
Used in Materials Science:
In materials science, 5-amino-1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonitrile could be explored for its potential to contribute to the development of new materials with specific properties. Its unique structure and functional groups may enable the creation of materials with applications in various industries.
Research on the properties and potential applications of 5-amino-1-(2,4-dimethylphenyl)-1H-pyrazole-4-carbonitrile is ongoing, and it is expected to continue to attract interest in the scientific community as new uses and applications are discovered.

Upstream product

• 123-06-8 Ethoxymethylenemalononitrile 
• 615-00-9 (2,4-dimethylphenyl)hydrazine 

Downstream Products

• 1452871-27-0 C₁₅H₁₅N₅O 
• 1452871-29-2 C₁₆H₁₇N₅O 
• 852313-94-1 5-amino-1-(2,4-dimethylphenyl)-1H-pyrazole-4-carboxamide 
• 852313-96-3 1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 

Relevant academic research and scientific papers

Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators

This letter describes the synthesis and SAR, developed through an iterative analogue library approach, of an mGluR4 positive allosteric modulator lead based on a pyrazolo[3,4-d]pyrimidine scaffold. Despite tremendous therapeutic potential, Compound 7, VU0080421, and related congeners represent only a handful of mGluR4 positive allosteric modulators ever described.

Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-a] and [3,4-d]pyrimidines

General, high-yielding MAOS protocols for the expedited synthesis of functionalized pyrazolo[1,5-a]pyrimidines and pyrazolo[3,4-b]pyrimidines, as well as their pyrazole precursors, are described amenable to an iterative analogue library synthesis strategy for lead optimization.

PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS

Pyrazolopyrimidine derivatives of formula (I), or a pharmaceutically acceptable salt thereof, are found to be active against hepatitis C infection, wherein: R1 is C6-C10 aryl, 5- to 10- membered heteroary1, -(C1-C4 alkyl)-(C6-C10 aryl) or -(C1-C4 alkyl)-(5- to 10- membered heteroaryl); R2 is a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10-membered heterocyclic ring; and X is -NR'-, -NR'-CO-NR''-, -NR'-L, or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C1-C6 alkyl group and L represents a C1-C6 alkylene group, the aryl, heteroaryl, heterocyclyl. and carbocyclyl moieties in the R1 and R2 substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl C1-C4alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro, C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'-CO2-R'', -CO2R'', -COR'''-NR'-CO-R''',-CONR'R'',SO2NR'R'',SO2R'''and -O-(CH2)n-R''' substituents, wherein n is from 0 to 4, each R’is the same or different and is hydrogen or C1-C6 alkyl, each R'' is the same or different and is hydrogen, C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, and each R'''' is the same or different and is C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heterocryl, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C1-C4 alkyl, C1-C4 hydroxyalkyl and C1-C4 haloalkyl groups.